Different biodistribution of 99'Tc-labelled chimeric mouse-human monoclonal antibody between athymic mice model and human
1996

Biodistribution of Chimeric Antibody in Mice and Humans

Sample size: 4 publication Evidence: moderate

Author Information

Author(s): N Oriuchi, N Watanabe, S Sugiyama, T Higuchi, K Imai, H Yamanaka, M Hashimoto, H Kanda, K Endo

Primary Institution: Gunma University School of Medicine

Hypothesis

The biodistribution of a chimeric mouse-human monoclonal antibody differs between athymic mice and human patients.

Conclusion

The study found that the chimeric antibody showed significantly different biodistribution in humans compared to the animal model, with a high accumulation in the liver.

Supporting Evidence

  • The chimeric antibody showed a high labeling efficiency and stability.
  • None of the patients showed adverse reactions after administration.
  • The first-phase plasma half-life of the antibody was found to be 6.4 minutes.
  • Significantly different biodistribution was observed between the animal model and human patients.

Takeaway

This study looked at how a special antibody behaves in mice and humans, finding that it acts very differently in the two.

Methodology

The study involved labeling a chimeric antibody with technetium-99m and administering it to both athymic mice and human patients to compare biodistribution.

Limitations

The study was limited to a small sample size of four patients.

Participant Demographics

Patients aged 63 to 74 years with metastatic bone tumors from prostate cancer.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication